JEFFREY LEIDEN - Corporate Board Profile

VERTEX PHARMACEUTICALS INC / MA

Filing Date	Source Excerpt
2020-04-28	Bruce I. Sachs elected to defer his quarterly cash retainers, which were paid in deferred stock units, on each of the quarterly payment dates occurring on the 15th of the month following the quarter end in an amount equal to the dollar value of the cash amount that would have been paid on such date divided by the fair market value of a share of common stock on each such date. The per share fair market values of our common stock on each of those dates was $182.28, $176.39, $175.50 and $231.55.
2021-04-08	Dr. Leiden became our Executive Chairman in April 2020. He was our Chief Executive Officer and President from 2012 through March 2020. He has been a member of our Board of Directors since July 2009, the Chairman of our Board of Directors since May 2012, and served as our lead independent director from October 2010 through December 2011. Dr. Leiden was a Managing Director at Clarus Ventures, a life sciences venture capital firm, from 2006 through January 2012. Dr. Leiden was President and Chief Operating Officer of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the Board of Directors of Abbott Laboratories from 2001 to 2006. From 1987 to 2000, Dr. Leiden held several academic appointments, including the Rawson Professor of Medicine and Pathology and Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School. He is an elected member of both the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences. Dr. Leiden serves as a director of Massachusetts Mutual Life Insurance Company, an insurance company, and serves as the Chairman of Revolution Healthcare Acquisition Corp., a special purpose acquisition corporation. Dr. Leiden was a director and the non-executive Vice Chairman of the board of Shire plc, a specialty biopharmaceutical company, from 2006 to January 2012, and a director of Quest Diagnostics, a medical diagnostics company, from December 2014 to May 2019. Dr. Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago.
2023-04-06	Dr. Leiden’s amended employment agreement provides for an annual cash payment in order to facilitate his participation in the company’s benefits plans. Pursuant to his amended agreement, Dr. Leiden received $65,000 in February 2022, received $67,000 in February 2023, and will receive an amount to be determined by the Board or MDCC in each of 2024 and 2025. ... Dr. Leiden received equity grants of $6.5 million in the first quarter of 2023 and will receive an annual equity grant of $6.5 million in each of the first quarters of 2024 and 2025 for his role as Executive Chairman. ... Dr. Leiden was our CEO and President through March 2020. ... Executive Chairman ... 2022 Total Compensation: $8,593,180.
2024-04-04	Jeffrey Leiden Executive Chairman Age 68 Director Since 2009 Board Committees: None 2023 Compensation: $6,595,282 Dr. Leiden possesses strong leadership qualities, demonstrated through his service as a senior executive in the biotechnology and pharmaceutical industries and as a life sciences venture capitalist, and has extensive knowledge of the science underlying drug discovery and development through his experiences as a distinguished physician, scientist, and teacher.
2025-04-03	Dr. Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago. Dr. Leiden possesses strong leadership qualities, demonstrated through his service as a senior executive in the biotechnology and pharmaceutical industries and as a life sciences venture capitalist. He has extensive knowledge of the science underlying drug discovery and development through his experiences as a distinguished physician, scientist, and teacher. As our former CEO and as a former senior executive at Abbott Laboratories, he brings a global perspective to our business and public policy issues facing our company. He also provides our board of directors with in-depth knowledge of our company and our corporate strategy. Dr. Leiden received $70,000 to facilitate his participation in the Company’s benefit plans, and $6.5 million of equity awards (determined based on grant date fair value, with PSUs determined based on target) consisting of $3.250 million in PSUs for which earned shares are based on one-year financial metrics and $3.250 million in immediately vested RSUs.